MAPT and myotonic dystrophy type 1: While in 2014, researchers discovered that both MBNL1 and MBNL2 have an enhancer activity of Tau exon 2 inclusion, and only the interaction of MBNL1 and MBNL2 can fully reverse the splicing defect of Tau exon 2 induced by the mutant CUG repeats, similar to that observed in DM1 (Carpentier et al., 2014).